Mondrian Investment Partners LTD Has $127.75 Million Stake in HCA Healthcare, Inc. (NYSE:HCA)

Mondrian Investment Partners LTD decreased its stake in HCA Healthcare, Inc. (NYSE:HCAFree Report) by 11.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 397,624 shares of the company’s stock after selling 52,281 shares during the period. HCA Healthcare comprises about 2.0% of Mondrian Investment Partners LTD’s holdings, making the stock its 21st largest holding. Mondrian Investment Partners LTD owned about 0.15% of HCA Healthcare worth $127,749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in HCA Healthcare by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 16,989,683 shares of the company’s stock worth $5,666,569,000 after purchasing an additional 60,304 shares during the last quarter. Sanders Capital LLC boosted its holdings in HCA Healthcare by 4.2% in the fourth quarter. Sanders Capital LLC now owns 11,404,003 shares of the company’s stock valued at $3,086,836,000 after acquiring an additional 456,738 shares during the last quarter. Wellington Management Group LLP raised its holdings in HCA Healthcare by 1.7% during the 4th quarter. Wellington Management Group LLP now owns 10,186,129 shares of the company’s stock worth $2,757,181,000 after purchasing an additional 170,560 shares during the last quarter. Royal Bank of Canada increased its position in shares of HCA Healthcare by 35.7% during the fourth quarter. Royal Bank of Canada now owns 4,503,918 shares of the company’s stock worth $1,219,121,000 after buying an additional 1,183,890 shares during the period. Finally, Capital World Investors lifted its holdings in HCA Healthcare by 57.5% in the first quarter. Capital World Investors now owns 2,792,377 shares of the company’s stock valued at $931,342,000 after buying an additional 1,019,750 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Trading Down 1.5 %

NYSE:HCA opened at $397.50 on Wednesday. The firm has a market cap of $104.11 billion, a price-to-earnings ratio of 19.82, a price-to-earnings-growth ratio of 1.46 and a beta of 1.67. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06. The firm has a 50-day moving average price of $365.55 and a two-hundred day moving average price of $339.06. HCA Healthcare, Inc. has a 52 week low of $215.96 and a 52 week high of $404.90.

HCA Healthcare (NYSE:HCAGet Free Report) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.97 by $0.53. The firm had revenue of $17.49 billion during the quarter, compared to the consensus estimate of $17.05 billion. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.29 EPS. On average, equities analysts expect that HCA Healthcare, Inc. will post 22.46 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 16th will be issued a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Monday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is 13.16%.

Insider Activity

In other HCA Healthcare news, SVP Kathryn A. Torres sold 1,857 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $355.05, for a total transaction of $659,327.85. Following the completion of the transaction, the senior vice president now owns 17,755 shares in the company, valued at $6,303,912.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Kathryn A. Torres sold 1,857 shares of HCA Healthcare stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $355.05, for a total value of $659,327.85. Following the completion of the transaction, the senior vice president now directly owns 17,755 shares in the company, valued at approximately $6,303,912.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at $11,438,494.76. The disclosure for this sale can be found here. Insiders have sold 17,202 shares of company stock valued at $6,407,273 in the last 90 days. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HCA. JPMorgan Chase & Co. boosted their price objective on HCA Healthcare from $327.00 to $332.00 and gave the company a “neutral” rating in a research note on Thursday, May 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $392.00 price objective on shares of HCA Healthcare in a research report on Monday, August 19th. Deutsche Bank Aktiengesellschaft increased their target price on shares of HCA Healthcare from $359.00 to $375.00 and gave the stock a “buy” rating in a research note on Friday, June 28th. Leerink Partners increased their price objective on shares of HCA Healthcare from $367.00 to $396.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Truist Financial upped their price target on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $359.89.

View Our Latest Report on HCA Healthcare

HCA Healthcare Profile

(Free Report)

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Read More

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCAFree Report).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.